Fulgent Genetics, Inc. (FLGT)

Market Cap	525.64M
Revenue (ttm)	283.47M
Net Income (ttm)	-42.71M
Shares Out	30.83M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	526,505
Open	16.83
Previous Close	16.85
Day's Range	16.52 - 17.19
52-Week Range	14.57 - 25.11
Beta	1.54
Analysts	Hold
Price Target	16.00 (-6.16%)
Earnings Date	May 2, 2025

About FLGT

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 29, 2016
• Employees: 1,313
• Stock Exchange: NASDAQ
• Ticker Symbol: FLGT
• Website: https://www.fulgentgenetics.com

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Analyst Forecast

According to one analyst, the rating for FLGT stock is "Hold" and the 12-month stock price forecast is $16.0.

Price Target

$16.0

(-6.16% downside)

Analyst Consensus: Hold